2015
Melanoma in situ Part II. Histopathology, treatment, and clinical management
Higgins HW, Lee KC, Galan A, Leffell DJ. Melanoma in situ Part II. Histopathology, treatment, and clinical management. Journal Of The American Academy Of Dermatology 2015, 73: 193-203. PMID: 26183968, DOI: 10.1016/j.jaad.2015.03.057.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAminoquinolinesBiopsy, NeedleCarcinoma in SituFemaleHumansImiquimodImmunohistochemistryImmunotherapyInjections, IntralesionalInterferon-alphaLaser TherapyMaleMelanomaMohs SurgeryNeoplasm InvasivenessNeoplasm StagingPrognosisRandomized Controlled Trials as TopicSkin NeoplasmsTreatment Outcome
2013
Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face
Hanlon A, Kim J, Leffell DJ. Intralesional interferon alfa-2b for refractory, recurrent squamous cell carcinoma of the face. Journal Of The American Academy Of Dermatology 2013, 69: 1070-1072. PMID: 24238178, DOI: 10.1016/j.jaad.2013.02.032.Peer-Reviewed Original Research
2000
Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis.
Carucci J, Leffell D. Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. JAMA Dermatology 2000, 136: 1415-6. PMID: 11074712, DOI: 10.1001/archderm.136.11.1415.Peer-Reviewed Original Research